Detail akcie Collegium Pharma online

Business Summary: Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Collegium Pharmaceutical Inc revenues increased 22% to $566.8M. Net income totaled $48.2M vs. loss of $25M. Revenues reflect Belbuca segment increase of 44% to $182.1M, Xtampza segment increase of 28% to $177.4M. Net Income reflects Acquisition Related expense decrease from $31.3M (expense) to $0K, Interest Income increase from $1M to $15.6M (income).